Contents
Issue 153 • April 2025
In association with
In Depth
Are European biopharma manufacturers ‘nearshoring’?
Inborn errors of metabolism elicit unique challenges for therapy development
GLP-1RAs and opioid use disorder: a new frontier in addiction treatment
European agencies catch up with speedier regulatory pathways for CGTs in the US
Q&A: USAID funding fallout: sponsors, and agencies may have to fill funding gap
Pfizer’s bet on gene therapies in haemophilia has been a bust